IN8bio, Inc. (INAB)
$
0.17
-0.03 (-17.65%)
Key metrics
Financial statements
Free cash flow per share
-0.5307
Market cap
18.4 Million
Price to sales ratio
4.9063
Debt to equity
0.6372
Current ratio
1.8440
Income quality
0.7834
Average inventory
0
ROE
-1.9715
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
IN8bio, Inc. is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of gamma-delta T cell therapies aimed at treating cancer. The company's lead product candidate, INB-200, is a genetically modified autologous gamma-delta T cell therapy currently undergoing Phase I clinical trials for glioblastoma and various solid tumors. Additionally, INB-100, an allogeneic product candidate, is in Phase I trials for patients with acute leukemia who are receiving hematopoietic stem cell transplantation. Further demonstrating its commitment to innovation, IN8bio is also advancing INB-400 and INB-300, both of which are in the preclinical stage for the treatment of different solid tumor cancers. The net income ratio is 0.00 reflecting the company's profitability margin. The net total of other income and expenses is $0.00 indicating the impact of non-core financial activities on the overall financial performance. The financial data pertains to the fiscal year 2024 showcasing the organization’s economic status during that period. The cost of revenue for the company is $0.00 highlighting its production and operational expenses, while the company incurred an income tax expense of $0.00 signaling its tax obligations as part of its financial responsibilities. With a market capitalization of $13,488,961.00 IN8bio, Inc. is classified as a small-cap player, reflecting its position within the marketplace. The stock is affordable at $0.18 making it suitable for budget-conscious investors seeking opportunities in the biotechnology sector. Furthermore, the stock enjoys a high average trading volume of 5,530,761.00 indicating strong liquidity and investor interest. As a key player in the Biotechnology industry, IN8bio contributes significantly to the overall market landscape, undertaking important research and development efforts. It belongs to the Healthcare sector, where it plays a crucial role in driving innovation and growth through its advanced therapeutic approaches.
What is IN8bio, Inc. (INAB)'s stock forecast?
Analysts predict IN8bio, Inc. stock to fluctuate between $0.16 (low) and $1.74 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is IN8bio, Inc.'s market capitalization?
As of 2025-04-01, IN8bio, Inc.'s market cap is $13,488,961, based on 81,258,800 outstanding shares.
How does IN8bio, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, IN8bio, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy IN8bio, Inc. (INAB) stock?
To buy IN8bio, Inc. (INAB) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for INAB. Place an order (Market, Limit, etc.).
What is the best time to invest in IN8bio, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did IN8bio, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.57 | Growth: -43%.
Where can I find IN8bio, Inc.'s investor relations reports?
Visit https://in8bio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for IN8bio, Inc.?
You can explore historical data from here
What is the all-time high and low for IN8bio, Inc. stock?
All-time high: $10.32 (2021-08-11) | All-time low: $0.16 (2025-03-31).
What are the key trends affecting IN8bio, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies, today unveiled INB-600, its potentially breakthrough next generation γδ T cell-based TCE platform. It is designed to address one of the biggest shortcomings of current existing γδ TCEs – insufficient numbers of γδ T cell effector cells to drive real clinical impact. This groundbreaking platform leverages γδ T cells' unique properties targeting applications in both oncology and autoimmune indications with potentially greater safety and tolerability than current CAR-T and TCE approaches.
globenewswire.com
IN8bio Reports Continued Progression-Free Survival in Phase 1 Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 ASH Conference
globenewswire.com
Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future INB-100 registrational trial INB-100 trial currently expanding enrollment up to approximately 25 patients at the recommended Phase 2 dose (RP2D) along with the potential to add additional centers and a prospective parallel observational cohort as a control Closed private placement for net proceeds of $11.6 Million in October 2024 extending cash runway through 2025 NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer, today reported financial results for the third quarter ended September 30, 2024, and recent corporate highlights.
globenewswire.com
Top Priority Clinical Program: Working to drive significant value creation with INB-100 for AML; ongoing trial is actively enrolling additional patients into the expansion cohort to further support the observed 100% progression-free survival in AML patients as of August 30, 2024. Suspending enrollment of Phase 2 clinical trial of INB-400 in newly diagnosed GBM; will continue to monitor patients for long-term remissions and overall survival in both INB-400 and INB-200 at UAB.
globenewswire.com
NEW YORK, Aug. 29, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc . (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the: H.C.
globenewswire.com
Received FDA guidance on the registrational path for INB-100 in acute myeloid leukemia (AML), an investigational allogeneic gamma-delta T cell therapy, with IND submission anticipated in Q1 2025. Early clinical data from investigator sponsored trials demonstrates prolonged relapse-free survival across both AML and glioblastoma (GBM) programs, compared to current standard-of-care, with both programs advancing to Phase 2 clinical development.
globenewswire.com
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will participate in a fireside chat during the H.C. Wainwright 2 nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024 at 2:30 p.m. ET.
globenewswire.com
100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, including high-risk and relapsed acute myeloid leukemia (AML) patients who had previously failed multiple lines of therapy, including CAR-T. Data continue to show long-term in vivo expansion and persistence of allogeneic gamma-delta T cells 365 days following a single administration, demonstrating first-ever durable persistence and expansion of an allogeneic cellular therapy.
globenewswire.com
92% of evaluable patients treated with INB-200 for glioblastoma exceeded a median progression-free survival (PFS) of seven months achieved with the standard-of-care regimen (Stupp regimen) Majority of fully dosed patients exceeded the expected median PFS based on age and tumor status; one patient from Cohort 2 remains alive and progression free at almost three years Radiologic evaluation indicative of “treatment effect” including changes in MRI enhancement and resolution of mid-line shift NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies, presented encouraging preliminary clinical data of INB-200 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 1, 2024. The preliminary data demonstrated that 92% of evaluable patients treated with INB-200 exceeded a median PFS of 7 months (median follow-up: 11.7 months) with concomitant temozolomide (TMZ), as of a data cutoff date of May 30, 2024.
globenewswire.com
NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced multiple presentations at the International Society for Cell & Gene Therapy 2024, to be held May 28th to June 1st in Vancouver, Canada. “ISCT is a scientific gathering renowned for fostering groundbreaking ideas and innovation in cellular therapies,” said Dr. Kate Rochlin, Chief Operating Officer of IN8bio.
See all news
